Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta
Authors:
- 1 January 2012
- book chapter
- Published by Elsevier
- Vol. 64, 27-81
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Institute on Aging (AG014449, AG034570, K01 AG037562, K23 AG031861, P01 AG025204, P50 AG005133, R37 AG025516, RO1 AG18402)
This publication has 275 references indexed in Scilit:
- Longitudinal assessment of Aβ and cognition in aging and Alzheimer diseaseAnnals of Neurology, 2011
- Spatial relation between microbleeds and amyloid deposits in amyloid angiopathyAnnals of Neurology, 2010
- APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal agingAnnals of Neurology, 2010
- Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's diseaseEMBO Molecular Medicine, 2009
- Influence of Cognitive Status, Age, and APOE-4 Genetic Risk on Brain FDDNP Positron-Emission Tomography Imaging in Persons Without DementiaArchives of General Psychiatry, 2009
- Detection of isolated cerebrovascular β‐amyloid with pittsburgh compound BAnnals of Neurology, 2008
- Aβ amyloid and glucose metabolism in three variants of primary progressive aphasiaAnnals of Neurology, 2008
- Alzheimer and frontotemporal pathology in subsets of primary progressive aphasiaAnnals of Neurology, 2008
- Frontotemporal dementia: Clinicopathological correlationsAnnals of Neurology, 2006
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004